|
Biodegradable products | Source | Availability | Benefits | Drawbacks | Reference |
|
Natural biodegradable products | Chitosan | Isolated from shrimps, crabs, insect shells, and cartilages | Biodegradability, biocompatibility, and mucosal immunity | Only acidic soluble and limited usage | [35, 36] |
Hyaluronic acid | From animal tissues and through fermentation of microbes | Biocompatibility and limited toxicity | High cost and no assurance of purity | [37, 38] |
Liposomes | Available as phospholipids and ceramides through self-assembly | Contains adjuvants with multiple layers | Instability and cannot be synthesized in abundance | [39ā41] |
Sodium alginate | Available in seaweed through microbial processes | Water soluble and retains more chitosan properties | No targets in complex phase | [42, 43] |
Synthetic biodegradable products | Chitosan by-products | Chitosan produced through chemical alteration | Enables incorporation of various antigens and immunomodulators | Toxicity due to inclusion of chemicals for synthesis | [36] |
PLGA | Obtained by the polymerization of lactic and glycolic acid | Used in most parts of the body including mucosa | Instability, more usage of required organic solvents and administration route through mucosa is ineffective | [44] |
Polyanhydrides | Available as methyl vinyl ether and maleic hydride | Enables sustained drug delivery and surface deprivation | Higher hydrolytic sensitivity with limited benefits | [45] |
Micelles | Using amphiphiles | Hydrophobic core incorporates water-soluble drugs | Inconsistency and not produced in abundance | [46] |
Poly-L lysine dendrigraft | By polycondensation of lysine | Mild toxicity and enables targeted delivery | Interference between immunogenicity and booster immunity and processes are quite complex | [47] |
|